600161 Stock Overview
Beijing Tiantan Biological Products Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Beijing Tiantan Biological Products Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥20.77 |
| 52 Week High | CN¥27.60 |
| 52 Week Low | CN¥20.17 |
| Beta | 0.36 |
| 1 Month Change | -6.02% |
| 3 Month Change | 0.92% |
| 1 Year Change | -17.55% |
| 3 Year Change | 5.91% |
| 5 Year Change | 34.72% |
| Change since IPO | 1,115.92% |
Recent News & Updates
Beijing Tiantan Biological Products Co., Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Oct 29
Beijing Tiantan Biological Products (SHSE:600161) Ticks All The Boxes When It Comes To Earnings Growth
Oct 27Calculating The Fair Value Of Beijing Tiantan Biological Products Co., Ltd. (SHSE:600161)
Oct 08Recent updates
Beijing Tiantan Biological Products Co., Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Oct 29Beijing Tiantan Biological Products (SHSE:600161) Ticks All The Boxes When It Comes To Earnings Growth
Oct 27Calculating The Fair Value Of Beijing Tiantan Biological Products Co., Ltd. (SHSE:600161)
Oct 08Beijing Tiantan Biological Products Co., Ltd.'s (SHSE:600161) Shares May Have Run Too Fast Too Soon
Sep 19Does Beijing Tiantan Biological Products (SHSE:600161) Deserve A Spot On Your Watchlist?
Jul 23Is Beijing Tiantan Biological Products Co., Ltd. (SHSE:600161) Expensive For A Reason? A Look At Its Intrinsic Value
Jun 09Beijing Tiantan Biological Products Co., Ltd.'s (SHSE:600161) Price Is Out Of Tune With Earnings
May 22We Think Beijing Tiantan Biological Products (SHSE:600161) Can Stay On Top Of Its Debt
Mar 16Do Beijing Tiantan Biological Products' (SHSE:600161) Earnings Warrant Your Attention?
Mar 01Shareholder Returns
| 600161 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -1.4% | -1.9% | -1.2% |
| 1Y | -17.6% | -16.2% | 11.8% |
Return vs Industry: 600161 matched the CN Biotechs industry which returned -17.6% over the past year.
Return vs Market: 600161 underperformed the CN Market which returned 10.9% over the past year.
Price Volatility
| 600161 volatility | |
|---|---|
| 600161 Average Weekly Movement | 4.2% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 600161 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600161's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1966 | 4,858 | Dao Xing Fu | www.tiantanbio.com |
Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and marketing of blood products in China and internationlly. Its products include human albumin; intravenous human immunoglobulin; rabies patient immunoglobulin; tetanus human immunoglobulin; hepatitis B human immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; histamine human immunoglobulin; human prothrombin complex; human coagulation factors VIII; human fibrinogen; recombinant human coagulation factor VIII for injection; and other blood products.
Beijing Tiantan Biological Products Co., Ltd. Fundamentals Summary
| 600161 fundamental statistics | |
|---|---|
| Market cap | CN¥41.07b |
| Earnings (TTM) | CN¥1.27b |
| Revenue (TTM) | CN¥5.23b |
32.2x
P/E Ratio7.9x
P/S RatioIs 600161 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600161 income statement (TTM) | |
|---|---|
| Revenue | CN¥5.23b |
| Cost of Revenue | CN¥2.35b |
| Gross Profit | CN¥2.89b |
| Other Expenses | CN¥1.61b |
| Earnings | CN¥1.27b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.64 |
| Gross Margin | 55.17% |
| Net Profit Margin | 24.36% |
| Debt/Equity Ratio | 0% |
How did 600161 perform over the long term?
See historical performance and comparisonDividends
0.6%
Current Dividend Yield20%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 15:12 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Beijing Tiantan Biological Products Co., Ltd. is covered by 25 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Changming He | BOCI Research Ltd. |
| Yue Gao | Changjiang Securities Co. LTD. |
| Pei Cheng | China Galaxy Securities Co., Ltd. |